APA (7th ed.) Citation

NJ, S., Y, A., A, E., D, R., SP, K., J, C., . . . KK, Z. (2026). Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma. JAMA network open, 9(5), e2614061. https://doi.org/10.1001/jamanetworkopen.2026.14061

Chicago Style (17th ed.) Citation

NJ, Shah, et al. "Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma." JAMA Network Open 9, no. 5 (2026): e2614061. https://doi.org/10.1001/jamanetworkopen.2026.14061.

MLA (9th ed.) Citation

NJ, Shah, et al. "Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma." JAMA Network Open, vol. 9, no. 5, 2026, p. e2614061, https://doi.org/10.1001/jamanetworkopen.2026.14061.